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Background. The inflammatory response following myocardial infarction (MI) is 
prerequisite for proper healing of infarcted tissue, but can also have detrimental effects on 
cardiac function. Interleukin (IL)-1α and IL-1β are potent inflammatory mediators and their 
bioactivity is tightly regulated by IL-1 receptor antagonist (IL-1ra) and soluble (s) IL-1 
receptors (R).  
Objectives. We aimed to examine whether levels of soluble regulators of IL-1 signalling are 
changed during ST-elevation MI (STEMI) and their associations with parameters of cardiac 
injury and ventricular remodelling.  
Methods. Plasma levels of IL-1Ra, sIL-1R1, sIL-1R2 and sIL-1R accessory protein (sIL-
1RAcP) were measured by immunoassays in repeated samples from patients with STEMI 
(n=272) and compared to healthy controls (n=65).  
Results. IL-1Ra, sIL-1R1 and sIL-1R2 levels were all significantly elevated after STEMI, 
while levels of sIL-1RAcP were lower compared to controls. sIL-1R2 levels (at different time 
points) correlated positively with C-reactive protein, myocardial infarct size and change in 
indexed left ventricular end-diastolic and end-systolic volume (LVEDVi and LVESVi) 
measured by cardiac MR acutely and after 4 months, and negatively with LV ejection fraction. 
Patients with >median levels of sIL-1R2 in the acute phase were more likely to have 
increased change in LVEDVi and LVESVi. Importantly, sIL-1R2 remained significantly 
associated with change in LVEDVi and LVESVi also after adjustment for clinical covariates.  
Conclusion. Levels of sIL-1R2 are independently associated with parameters of LV adverse 
remodelling following STEMI. 
 





Inflammation has dual role in cardiovascular disease. It is suggested to play a pivotal role in 
all stages of coronary artery disease from development of atherosclerotic plaques to plaque 
rupture and thrombus formation, but is also involved in cardiac repair and remodelling 
following myocardial infarction (MI) [1, 2]. The inflammatory response following MI 
involves cytokine release and infiltration of neutrophils and monocytes, which is prerequisite 
for proper healing of damaged cardiac tissue. However, excessive inflammation may cause 
collateral damage and have detrimental effects on cardiac function both in the short and long 
term [1, 2]. Clinical trials have found that targeting interleukin (IL)-1 in acute coronary 
syndromes by recombinant IL-1 receptor antagonist (IL-1Ra) has anti-inflammatory effects 
accompanied by reduced ventricular remodelling [3, 4], and neutralization of IL-1 was very 
recently shown to induce a lower rate of recurrent cardiovascular events in patients with 
previous MI [5]. However, the regulation of IL-1 related molecules, in the complex IL-1 
system, following MI are still not clear. 
IL-1α and IL-1β are potent upstream mediators of inflammation and their activity is regulated 
at several levels (Figure 1) [6]. IL-1α is often classified as an alarmin and is typically 
membrane associated and rarely detectable in circulation [6]. Activation and secretion of IL-
1β is a two-step process involving inflammasomes [6]. IL-1 (both α and β) binds the type I 
IL-1 receptor (IL-1R1) resulting in recruitment of the co-receptor IL-1 receptor accessory 
protein (IL-1RAcP), which is required for signal transduction (Figure 1A). To avoid an 
excessive inflammatory response, IL-1 activity is tightly regulated at the receptor level [6]. 
IL-1 receptor antagonist (IL-1Ra) competes with IL-1 for binding to IL-1R1 (Figure 1B). 
Moreover, type II IL-1 receptor (IL-1R2) lacks the ability to initiate signalling and acts as a 
decoy receptor (Figure 1C). Finally, the extracellular domain of all IL-1 receptors may be 
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shed from the cell surface and act as soluble (s) negative regulators of IL-1 signalling (i.e., 
sIL-1R1, sIL-1R2 and sIL-1RAcP; Figure 1D-G). sIL-1R2 may be of particular importance 
since binding to IL-1 is nearly irreversible [6], whereas sIL-1R1 also binds IL-1Ra and may 
therefore also have an inflammatory effect.  
We have previously shown elevated levels of IL-1β during acute ST segment elevation MI 
(STEMI) and an association with subsequent left ventricular (LV) hypertrophy and 
remodelling [7]. Others and we have also shown that IL-1Ra is increased in the acute phase of 
MI [7-9], but not much is known about levels of the soluble IL-1 related receptors which 
clearly influence the net activity in IL-1 related pathways. Herein, we examined levels of 
soluble regulators of IL-1 signalling in STEMI as well as their associations with parameters of 
cardiac injury and ventricular remodelling. 
 
Material and methods 
Study population 
Samples from the previously reported Post-conditioning in ST-Elevation Myocardial 
Infarction (POSTEMI; www.clinicaltrail.gov; NCT00922675) trial [10] were investigated and 
consisted of 272 patients with first-time STEMI with symptoms of <6 hours and with typical 
changes in ECG with >1 mm elevation in the ST-segment in at least two contiguous extremity 
leads or >2mm elevation of the ST-segment in at least two contiguous precordial leads or 
new-onset left-bundle branch block and with successful opening of the occluded coronary 
vessel after one balloon inflation. Patients were randomized to standard reperfusion or to four 
repeated occlusions of the coronary vessel of one minute duration starting one minute after 
the first opening of the artery. Patients with previous MI or with renal failure (serum 
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creatinine >200 µmol/L), unstable patients with cardiogenic shock, pulmonary congestion, 
hypotension or cardiac arrest were not included in the study. Sixty-five healthy age and sex-
matched individuals were included as controls.  
The study was approved by the Regional Ethics committee and conducted in accordance with 
the principles of the declaration of Helsinki and all patients provided written informed consent. 
Cardiac magnetic resonance imaging (CMR) 
CMR was performed in the acute phase (median 2 days following MI) and after four months 
and has previously been described in detail [10]. Briefly, CMR was performed on a 1.5-T 
scanner (Philips Intera, release 11 or Philips Achieva, release 3.2, Philips Healthcare, Best 
Netherlands). The patients were examined in the same scanner at both occasions. Image 
analyses were performed on an extended MR workspace (Philip Medical Systems). LV 
volume analyses were performed on short axis images. Analysis of area at risk, defined as 
myocardium with signal intensity of more than two standard deviations above the signal 
intensity in non-infarcted remote myocardium, was performed on T2 weighted images in the 
short axis plane. Infarct size was determined in two- and four-chamber, long and short axis 
views 15 minutes following contrast injection (Gadolinium-DTPA 469 mg/ml, 0.15 mmol/kg, 
Magnevist, Schering AG, Germany). Myocardial salvage index (%) was calculated as follow: 
(area at risk- infarct size at 4 months/ area at risk) x 100. Microvascular obstruction (MVO) 
was defined as dark areas within the infarcted myocardium. 
Blood sampling protocol 
Blood samples were drawn before and immediately after the percutaneous coronary 
intervention (PCI) procedure, at day 1 following the procedure and after 4 and 12 months. 
EDTA-blood was placed on crushed ice and within 30 minutes centrifuged at 3000g for 20 




EDTA-plasma levels of sIL-1R1, sIL-1R2, sIL-1RAcP were analysed by enzyme 
immunoassays from R&D Systems (DuoSet), while IL-1Ra was measured using an enzyme 
immunoassay from Peprotech (Rocky Hill, NJ). 
Statistical analyses 
Differences between groups were analysed with the use of Mann-Whitney U tests. When 
comparing ≥3 groups, Kruskal-Wallis test with Dunn’s multiple comparison test was used. 
Univariate repeated measures ANOVA was used to assess changes in protein levels over time 
during STEMI. Associations between variables were assessed by means of Spearman 
correlation coefficient. To further assess possible associations between sIL-1R2 and LV 
remodelling, multiple linear regression analyses were performed with change in indexed LV 
end-diastolic volume (LVEDVi) and LV end-systolic volume (LVESVi) from STEMI to 4-
month follow-up as outcome variables, respectively. The following covariates were entered 
into the models based on either clinical relevance or an association with either sIL-1R2 or the 
dependent variable in univariable analyses with a p-value <0.2: Age, gender, hypertension, 
diabetes mellitus, time from symptom onset to PCI, infarct localization (anterior MI vs 
inferior or posterior MI), treatment with ischemic postconditioning, peak troponin T, peak C-
reactive protein (CRP), N-terminal brain natriuretic peptide (NT-proBNP) on admission and 
haemoglobin on admission. As a result of skewness, the following continuous variables were 
logarithmically transformed with the natural logarithm (ln): Time from symptom onset to PCI, 
troponin T, CRP, and NT-proBNP. Pairwise deletion was used to handle missing data in 
multivariable analyses. Collinearity was assessed by the variance inflation factor in all 
multivariable models. A p-value <0.05 was considered statistically significant. All analyses 





Temporal changes in plasma levels of IL-1 signalling regulators after STEMI  
We analysed plasma levels of regulators of IL-1 signalling in 272 patients with STEMI from 
the POSTEMI trial [10], and 65 healthy controls (age 66 [25, 75 percentile: 46, 68]; 52% 
men). Baseline characteristics are shown in Table 1. Samples were acquired immediately 
before and immediately after end of the PCI procedure, at day 1 after PCI (median 18.3 hours 
after PCI) and at 4-month and 12-month follow-up. At baseline, before PCI, the STEMI 
population was characterized by increased levels of IL-1Ra, sIL-1R1 and sIL-1R2 and 
decreased levels of sIL-1RAcP as compared with healthy controls (Figure 2). IL-1Ra levels 
peaked right after PCI, but remained elevated even one year after STEMI. sIL-1R1 levels 
were at their highest before PCI and thereafter decreased, ending up lower than controls at 4 
and 12-month follow-up. Notably, however, the elevated levels of sIL-1R2 and decreased sIL-
1RAcP levels remained stable throughout the study. The ischemic post-conditioning 
procedure did not affect levels of IL-1 regulators (data not shown). 
Levels of soluble IL-1 modulators in relation to measures of myocardial injury and 
remodelling as assessed by CMR after STEMI 
We then studied the associations between soluble regulators of IL-1 signalling and markers of 
myocardial damage and remodelling. There was no association between levels of IL-1Ra and 
sIL-1R1 and CMR data during the acute phase or CMR data after 4 months (Table 2, 
Supplementary Table S1 and S2). In contrast, sIL-1RAcP and in particular sIL-1R2 showed 
some interesting associations (Table 2, Supplementary Table S3 and S4). Whereas sIL-1RAcP 
was inversely correlated with infarct size measured acutely and at 4 months’ follow-up, sIL-
1R2 measured in the acute phase was associated with LV ejection fraction (LVEF) and infarct 
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size measured acutely (negative and positive correlation, respectively) and change in indexed 
LV end-diastolic volume (LVEDVi) and LV end-systolic volume (LVESVi) from acute 
STEMI to 4 months’ follow up (Table 2). Based on these data, we analysed sIL-1R2 further 
with respect to its association with markers of myocardial injury and LV remodelling.  
Soluble IL-1R2 is independently associated with measures of myocardial injury and 
remodelling after STEMI 
When the STEMI patients were dichotomized according to plasma levels of sIL-1R2 (i.e. 
above or below median) at different time points after STEMI, several significant findings 
were revealed. First, sIL-1R2 measured at day 1 were associated with infarct size (p=0.04), 
LVEF (p=0.03) and area at risk (p=0.003) during the acute phase (Table 3). Second, there was 
a significant association between presence of microvascular obstruction (MVO) and levels of 
sIL-1R2 measured immediately before and after PCI (Table 3; p=0.001 and p=0.009, 
respectively). Third, patients with high levels of sIL-1R2 before PCI also had lower LVEF 
determined by CMR at four months. Fourth, the change in LVEDVi and LVESVi from the 
acute phase to four months were significantly higher in patients with high (above median) 
compared to low (below median) levels of sIL1-R2 at admission (sampled immediately before 
and after PCI) and at day 1 (Figure 3A-B). Finally, sIL-1R2 at all sampling points during 
hospitalisation remained significantly associated with an increase in LVEDVi (≈3.2-3.9 ml/m2 
per standard deviation change in sIL-1R2) and LVESVi (≈2.4-3.0 ml/m2 per standard 
deviation change in sIL-1R2) also after adjustment for relevant clinical covariates in two 
multivariable linear regression models (Figure 3C-D; Supplementary Table S5 and S6).  
A similar approach with dichotomizing the patient group according to sIL-1RAcP 
levels, did not indicate any link between sIL-1RAcP and markers of LV remodelling, but 
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there was a significant association between infarct size measured at 4 months and sIL-1RAcP 
measured after PCI (p=0.004) and at follow up (p=0.008) (Supplementary Table S7). 
 
Discussion 
Dysregulated IL-1 signalling following MI can disturb infarct healing, but can also cause 
collateral damage and promote acute cardiac dysfunction and contribute to maladaptive LV 
remodelling. A complex regulation of IL-1 activity occurs at the receptor level, and here we 
show that levels of soluble regulators of IL-1 receptor signalling are changed in a population 
of patients with STEMI. Moreover, we show that plasma levels of sIL-1R2 remained elevated 
in the acute phase and during long-term follow-up, strongly associated with development of 
LV remodelling, as evaluated as change in LVEDVi and LVESVi, even after adjustment for 
multiple clinical covariates. 
Levels of soluble IL-1 regulators in disease states have been reported in a few studies, 
including our previous study in patients with chronic HF [11-13]. Herein we examined these 
IL-1 regulators following STEMI. Notably, our findings on the temporal changes in IL-1Ra 
and sIL-1R2 in STEMI patients resemble results from patients with septic shock [14]. While 
plasma IL-1Ra peaked with high values during acute STEMI and decreased markedly up to 
day 1, sIL-1R2 levels were moderately higher than in healthy controls, but intriguingly, this 
difference was sustained even 12 months after the ischemic event. IL-1R2 is a decoy receptor 
with greater affinity for IL-1β than IL-1Ra [6], and these effects are maintained also when IL-
1R2 is shed from the cell surface. Conversely, IL-1Ra has higher affinity for IL-1R1 than for 
IL-1R2 and this avoids that the decoy receptor neutralizes the receptor antagonist. Thus, IL-
1Ra and sIL-1R2 represent two complementary mechanisms of negative IL-1 regulation, and 
during and after MI they have distinct temporal profiles. Previous studies have demonstrated 
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an association between IL-1Ra and myocardial necrosis during MI [8, 15]. We did, however, 
not observe this in the present study, but the correlation with CRP supports the previously 
reported association with the acute phase response and that IL-1Ra may be a marker of acute 
inflammation. In contrast, the increase in sIL-1R2 was more moderate and persisted 
throughout the observation period. Interestingly, whereas IL-1Ra may be a marker of acute 
systemic inflammation, the increase in sIL-1R2 has been suggested to be more targeted to 
local tissue inflammation [12]. Thus, it is tempting to hypothesize that sIL-1R2 is a better 
marker of IL-1 activity in the infarcted heart than IL-1Ra which is primarily a reflection of the 
acute phase response, but this will have to be more thoroughly addressed in future studies.  
 While most cells express IL-1R1, expression of IL-1R2 is restricted with neutrophils 
and monocytes as major sources [12]. Anti-inflammatory stimuli (e.g. glucocorticoids and IL-
4) increase neutrophil expression of IL-1R2, while inflammatory signals (e.g. IL-1, tumour 
necrosis factor [TNF] and reactive oxygen species) promote the proteolytic cleavage and 
release of sIL-1R2 [12]. Neutrophils are centrally involved in initiating inflammatory 
processes, but are also essential in inflammation resolution, and this at least partly involves 
expression and release of IL-1R2 [16, 17], which may dampen the response to IL-1 in both 
macrophages and fibroblasts [18, 19]. Saxena et al. characterized the IL-1R expression profile 
in cells infiltrating the infarcted mouse myocardium [20] and demonstrated that the initial 
inflammatory phase of cardiac repair was characterized by cells primarily expressing IL-1R1, 
while IL-1R2 dominated in later stages [20]. This pattern fits well with what we observe 
during STEMI, with initially high levels of sIL-1R1 that decrease rapidly, while sIL-1R2 
levels remain elevated. We hypothesize that even after the acute stages of STEMI, there is a 
persistent non-resolving IL-1 mediated myocardial inflammation, at least partly kept under 
control by IL-1R2, as reflected by elevated plasma levels of sIL-1R2. 
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 Inflammation has been suggested to be a significant contributor to ventricular 
remodelling after MI [2, 15, 21]. The major finding in the present study was that high levels 
of sIL-1R2 during the acute phase were significantly associated with ventricular remodelling 
evaluated as change in LVEDVi and LVESVi from the hospitalization to 4 months. An 
explanation for the association between high sIL-1R2 levels and adverse myocardial 
remodelling could be that increased sIL-1R2 levels represent a counteracting mechanism to 
enhanced inflammation such as has been reported in septicaemia [14]. This intriguing finding 
may also indicate that inhibiting IL-1 signalling by this soluble receptor, that strongly and 
irreversibly bind IL-1, may be harmful during the acute phase. Whereas IL-1Ra has been 
suggested to have beneficial effects when administered during MI [3], the near irreversible 
binding of sIL-1R2 to IL-1 during the acute phase could potentially attenuate adaptive 
remodelling and infarct healing induced by IL-1 and thereby promote increased infarct size 
and maladaptive remodelling during follow-up. This concept could have important 
therapeutical consequences when targeting the IL-1 system during MI.  
Soluble IL-1RAcP appeared as the only IL-1 signalling regulator that was 
downregulated in the acute phase of STEMI. Soluble IL-1RAcP levels during the acute phase 
were also negatively correlated with infarct size both during the acute phase and at 4 months’ 
follow-up as assessed by CMR imaging. IL-1RAcP is the main signalling unit of the IL-1 
receptor complex [6]. However, when IL-1RAcP is solubilized, it turns into a negative 
regulator of IL-1 signalling [6]. This can potentially occur through inhibition of the 
interaction between IL-1R1/IL-1 and IL-1RAcP. However, sIL-1RAcP has also been shown 
to 100-fold increase the affinity of IL-1 bound to sIL-1R2 [22], and interestingly, sIL-1R2 and 
sIL-1RAcP bind pro-IL-1β with high affinity and block its processing by caspase-1 and 
thereby not only attenuate the effect of IL-1 but also its production [23]. The observed 
reduction of sIL-1RAcP could therefore have potentially pro-inflammatory net effects. 
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However, its interaction with sIL-1R2 is complex and the net effect of the demonstrated 
pattern with increased sIL-1R2 and decreased sIL-1RAcP is at present not clear.  
The present study has some limitations such as lack of exact data on lipid levels on the 
STEMI patients prior to admission (i.e., before start of statin therapy). Moreover, levels of IL-
1Ra have previously been found to be elevated in patients with stable coronary artery disease  
[24], but we do not know if levels the other soluble IL-1 regulators are affected by the 
atherosclerotic process per se. Future studies will have to address this issue, which could 
potentially affect how we interpret the effect of STEMI on levels of soluble levels of IL-1 
signalling. Nonetheless, our data demonstrate a complex regulation of the IL-1 system during 
STEMI, and suggest that sIL-1R2 could be a hereto unrecognized mediator and marker of 
myocardial remodelling in these patients. Our data also illustrate the delicate balance between 
too much and too little IL-1 activity following MI.  
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Figure 1. Regulators of Interleukin (IL)-1 signalling. 
IL-1 (IL-1α or IL-1β) binds to IL-1 receptor 1 (IL-1R1), IL-1R accessory protein (IL-1RAcP) 
is recruited and signaling initiated (A). IL-1 receptor antagonist (IL-1Ra) binds IL-1R1 with 
high specificity, but does not trigger downstream signaling (B). IL-1R2 binds IL-1, but do not 
initiate signaling (C). Soluble (s) IL-1R2 binds and neutralizes IL-1 with high affinity (D), 
while sIL-1R1 has preferential affinity for IL-1Ra (E). Soluble (s) IL-1RAcP may either 
inhibit formation of the signaling complex (F) or stabilize the binding of IL-1 to sIL-1R2 (G). 
 
Figure 2. Temporal profile of soluble regulators of IL-1 signalling during the course of 
STEMI.  
Levels of (A) IL-1 receptor antagonist (IL-1Ra), (B) soluble IL-1 receptor 1 (sIL-1R1), (C) 
sIL-1R2 and (D) sIL-1R Accessory protein (sIL-1RAcP) were measured in 65 healthy 
controls and 255 STEMI patients before and immediately after percutaneous coronary 
intervention (PCI), at Day 1 (median 18.3 hours after PCI) and at 4 and 12 months’ follow-up. 
Circles and error bars indicate geometric means and 95% confidence intervals. **p<0.01, 
***p<0.001 and ****p<0.0001 vs controls (Kruskal-Wallis comparing controls and STEMI at 
different time points with Dunn’s multiple comparisons test). P-values in graphs indicate 




Figure 3. Soluble interleukin-1 receptor 2 (sIL-1R2) levels are associated with 
ventricular remodelling after STEMI.  
sIL-1R2 levels were measured before and immediately after PCI and at Day 1 (median 18.3 
hours after PCI). Change in indexed left ventricular end-diastolic volume (LVEDVi) and end-
systolic volume (LVESVi) were determined in 224 patients with ST-elevation myocardial 
infarction (STEMI) based on CMR in the acute phase and at 4-months’ follow-up. (A). 
Change in LVEDVi and (B) change in LVESVi according to low or high levels of sIL-1R2 
(i.e. < or > median) in the acute phase of STEMI. Bars are means ± 95% confidence intervals 
(CI). C and D. Forest plots of β coefficients, 95% CI and p-values from univariable (Uni) and 
multivariable linear regression analyses on associations between sIL-1R2 measured at day 1 
post-STEMI and changes in LVEDVi (C) and LVESVi (D). Model 1 adjusts for clinical 
variables, while Model 2 also includes C-reactive protein (CRP) and troponin T (TnT). 
Results from the most important adjustment variables are shown for comparison. Coefficients 
(β) are expressed as change in LVEDVi or LVESVi per 1 standard deviation (SD) change in 
the independent variable. Adm, admission; NT-proBNP, N-terminal pro-brain natriuretic 




Table 1. Baseline characteristics of the patient population in the POSTEMI trial. 
 
 
Patients with ST-elevation myocardial infarction 
(n=272) 
Age 60 (53, 67) 
Male gender 223 (82%) 
Body mass index (kg/m2) 26.6 (24.4, 29.1) 
Hypertension 73 (26.8%) 
Hypercholesterolemia 26 (9.6%) 
Diabetes mellitus 17 (6.3%) 
Current smoker 139 (51.1%) 
Time from symptom to PCI (min) 179 (123, 261) 
Anterior MI* 131 (48.2%) 
Multi-vessel disease 90 (33.1%) 
Peak troponin T (ng/L) 5865 (3302, 10337) 
Peak C-reactive protein (mg/L) 18 (7, 45) 
Admission NT-proBNP (pmol/L) 9 (5, 22) 
Admission creatinine (μmol/L) 70 (62, 81) 
Data are presented as median (25th, 75th percentile) or numbers (%). *Anterior myocardial 
infarction (MI) vs inferior or posterior MI. POSTEMI, postconditioning in ST-elevation 
myocardial infarction; PCI, percutaneous coronary intervention; NT-proBNP, N-terminal pro-




Table 2. Correlations between soluble IL-1 regulators and measures of cardiac injury and 
function.  
 
 IL-1Ra sIL-1R1 sIL-1R2 sIL-1RAcP 
Infarct size, acute 0.06 0.000 0.15* -0.19** 
Infarct size, 4 months 0.08 -0.02 0.09 -0.17* 
Ejection fraction, acute -0.14 -0.07 -0.15* 0.06 
Ejection fraction, 4 months -0.07 -0.06 -0.12 0.10 
Area at risk  0.07 -0.07 0.12 -0.11 
Myocardial salvage -0.03 -0.06 -0.10 0.09 
LVEDVi 0.10 -0.02 0.21** -0.04 
LVESVi 0.12 -0.05 0.16* -0.06 
Peak troponin T 0.10 0.01 -0.17** -0.17** 
Peak C-reactive protein 0.35** 0.03 0.19** -0.13 
Admission NT-proBNP 0.09 0.12 -0.20** -0.03 
Symptom to PCI time -0.03 -0.11 -0.06 -0.14* 
Correlations are based on plasma levels of interleukin-1 receptor antagonist (IL-1Ra), soluble 
(s) IL-1R1, sIL-1R2 and sIL-1R accessory protein (sIL-1RAcP) measured day 1 (median 18.3 
hours after PCI) after ST-elevation myocardial infarction (STEMI; n=255-272). LVEDVi 
(indexed end-diastolic volume of LV) and LVESVi (indexed end-systolic volume of LV) 
were calculated from cardiac magnetic resonance imaging acquired in the acute phase and 
after 4 months. NT-proBNP, N-terminal pro-brain natriuretic peptide. Numbers are given as 
Spearman’s rho correlation coefficients. *p<0.05, **p<0.01. 
 
Table 3. Myocardial injury and function measured by CMR according to sIL-1R2 values. 
 sIL-1R2 before PCI sIL-1R2 after PCI sIL-1R2 day 1 sIL-1R2 4 months 
 < median > median P-value < median > median P-value < median > median P-value < median > median P-value 
CMR in  
acute phase 
            
IS, %LV mass 15.8 18.2 0.07 16.6 17.9 0.45 15.5 19.2 0.04    
LVEF, % 52 51 0.30 52 51 0.40 53 49 0.03    
Area at risk, %LV 41.1 43.5 0.15 40.8 43.3 0.11 38.0 44.8 0.003    
MVO (presence) 41(39.4%) 68 (61.3%) 0.001 46 (41.1%) 64 (58.7%) 0.009 47 (44.8%) 57 (53.8%) 0.19    
LVEDVi, mL/m2 83.7 83.8 0.97 84.8 80.3 0.31 83.6 84.2 0.88    
LVESVi, mL/m2 38.8 39.9 0.66 41.2 38.7 0.97 38.2 41.5 0.22    
CMR after 
4 months 
            
IS, %LV mass 13.6 14.5 0.13 13.8 13.8 0.33 13.5 13.8 0.28 14.0 14.0 0.44 
LVEF, % 58 53 0.006 57 54 0.11 57 55 0.13 56 55 0.57 
MS, % 54.4 48.4 0.07 54.2 50.5 0.07 51.0 52.2 0.75 52.5 51.1 0.18 
LVEDVi, mL/m2 80.5 88.6 0.006 85.3 86.7 0.19 84.8 86.7 0.09 86.1 86.8 0.61 
LVESVi, mL/m2 33.3 39.8 0.002 36.4 38.0 0.11 35.9 38.0 0.08 37.9 37.9 0.54 
Levels of soluble interleukin-1 receptor 2 (sIL-1R2) were measured before and immediately after percutaneous coronary intervention (PCI), at Day 1 
(median 18.3 hours after PCI) and at 4-months’ follow-up in 255 ST-elevation myocardial infarction (STEMI) patients. Data are presented as median 
or numbers (%). P-values were determined by Mann-Whitney U test. CMR, cardiac magnetic resonance imaging; IS, infarct size; LV, left ventricle; 
LVEF, LV ejection fraction; MVO, microvascular obstruction; LVEDVi, indexed end-diastolic volume of LV; LVESVi, indexed end-systolic volume 
of LV; MS, myocardial salvage. 
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